Despite failing to hit their primary endpoints, two trials show cardioprotective benefits with two common heart drugs in patients with cancer. The question is how to get everyone on board.
Medscape Medical News
Original Article: Chipping Away at Chemotherapy-Induced Cardiotoxicity
NEXT ARTICLE